IHL Insider Trading

Insider Ownership Percentage: 26.56%
Insider Buying (Last 12 Months): A$1,583.23
Insider Selling (Last 12 Months): A$0.00

Incannex Healthcare Insider Trading History Chart

This chart shows the insider buying and selling history at Incannex Healthcare by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Incannex Healthcare Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for IHL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Incannex Healthcare Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2023Joel LathamInsiderBuy1,583,227A$0.00A$1,583.23
10/6/2021Sudhanshu AgarwalInsiderBuy20,999,500A$0.20A$4,199,900.00
9/21/2021Peter WiddowsInsiderExercise657,895A$0.08A$52,631.60
9/6/2021Sudhanshu AgarwalInsiderBuy20,000,000A$0.20A$4,000,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Incannex Healthcare (ASX:IHL)

7.47% of Incannex Healthcare stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Incannex Healthcare logo
Incannex Healthcare Limited, a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Docklands, Australia.
Read More on Incannex Healthcare

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


627,285 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Incannex Healthcare?

Incannex Healthcare's top insider investors include:
  1. Joel Latham (Insider)
Learn More about top insider investors at Incannex Healthcare.